Traci Lyons
Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 23 | 2024 | 2139 | 4.060 |
Why?
| Semaphorins | 6 | 2021 | 25 | 3.250 |
Why?
| Antigens, CD | 7 | 2021 | 479 | 2.870 |
Why?
| Lymphatic Vessels | 6 | 2024 | 60 | 2.750 |
Why?
| Mammary Glands, Human | 6 | 2024 | 64 | 2.660 |
Why?
| Postpartum Period | 11 | 2022 | 330 | 2.310 |
Why?
| Cyclooxygenase 2 | 6 | 2020 | 172 | 2.100 |
Why?
| Mammary Glands, Animal | 8 | 2024 | 121 | 1.870 |
Why?
| Breast | 6 | 2024 | 152 | 1.440 |
Why?
| Gene Expression Regulation, Neoplastic | 6 | 2022 | 1333 | 1.040 |
Why?
| Epithelial Cells | 4 | 2024 | 1036 | 1.030 |
Why?
| Lymphangiogenesis | 4 | 2024 | 25 | 0.970 |
Why?
| GPI-Linked Proteins | 6 | 2021 | 67 | 0.840 |
Why?
| Macrophages | 4 | 2020 | 1463 | 0.810 |
Why?
| Puerperal Disorders | 2 | 2014 | 30 | 0.770 |
Why?
| Tumor Microenvironment | 8 | 2022 | 618 | 0.760 |
Why?
| Receptors, Estrogen | 3 | 2021 | 428 | 0.760 |
Why?
| Anoikis | 1 | 2021 | 32 | 0.750 |
Why?
| Mammary Neoplasms, Animal | 3 | 2016 | 30 | 0.730 |
Why?
| Antineoplastic Agents, Hormonal | 2 | 2020 | 158 | 0.720 |
Why?
| Extracellular Matrix | 5 | 2021 | 497 | 0.700 |
Why?
| Drug Resistance, Neoplasm | 2 | 2021 | 749 | 0.630 |
Why?
| Cell Line, Tumor | 11 | 2024 | 3160 | 0.590 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 231 | 0.580 |
Why?
| Lactation | 4 | 2022 | 170 | 0.560 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2019 | 226 | 0.550 |
Why?
| Mice | 18 | 2024 | 16579 | 0.510 |
Why?
| Neoplasm Metastasis | 5 | 2020 | 608 | 0.510 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2016 | 54 | 0.500 |
Why?
| NF-kappa B | 1 | 2019 | 651 | 0.500 |
Why?
| Animals | 23 | 2024 | 34501 | 0.470 |
Why?
| Proto-Oncogene Proteins c-akt | 3 | 2021 | 421 | 0.470 |
Why?
| Neoplasm Recurrence, Local | 1 | 2020 | 957 | 0.470 |
Why?
| Biomarkers, Tumor | 2 | 2020 | 1182 | 0.460 |
Why?
| Pregnancy Complications, Neoplastic | 3 | 2020 | 52 | 0.450 |
Why?
| Xenograft Model Antitumor Assays | 4 | 2020 | 810 | 0.410 |
Why?
| Pregnancy | 10 | 2024 | 6297 | 0.410 |
Why?
| Cell Movement | 6 | 2022 | 937 | 0.410 |
Why?
| Female | 27 | 2024 | 68127 | 0.400 |
Why?
| Carcinoma, Ductal | 1 | 2011 | 11 | 0.380 |
Why?
| Fibrillar Collagens | 1 | 2011 | 14 | 0.380 |
Why?
| Disease Models, Animal | 5 | 2020 | 3943 | 0.360 |
Why?
| Mice, Inbred BALB C | 3 | 2019 | 1229 | 0.350 |
Why?
| Neoplasm Invasiveness | 5 | 2020 | 480 | 0.320 |
Why?
| Antigens, Differentiation, Myelomonocytic | 2 | 2019 | 60 | 0.310 |
Why?
| Humans | 30 | 2024 | 128524 | 0.300 |
Why?
| Cell Survival | 2 | 2021 | 1077 | 0.280 |
Why?
| Membrane Glycoproteins | 2 | 2019 | 466 | 0.260 |
Why?
| Mice, SCID | 2 | 2020 | 345 | 0.250 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2007 | 153 | 0.250 |
Why?
| Mice, Inbred C57BL | 4 | 2021 | 5257 | 0.250 |
Why?
| Prognosis | 4 | 2020 | 3780 | 0.250 |
Why?
| Cell Transformation, Neoplastic | 2 | 2021 | 325 | 0.250 |
Why?
| Apoptosis | 2 | 2020 | 2437 | 0.240 |
Why?
| Mice, Inbred NOD | 3 | 2021 | 582 | 0.230 |
Why?
| Mice, Knockout | 3 | 2022 | 2752 | 0.230 |
Why?
| Chitin | 1 | 2024 | 8 | 0.230 |
Why?
| Chitinases | 1 | 2024 | 9 | 0.230 |
Why?
| Lymphatic System | 1 | 2024 | 12 | 0.230 |
Why?
| Lymphatic Metastasis | 4 | 2024 | 318 | 0.220 |
Why?
| Celecoxib | 2 | 2014 | 39 | 0.210 |
Why?
| Biology | 1 | 2024 | 83 | 0.210 |
Why?
| Head and Neck Neoplasms | 2 | 2020 | 534 | 0.200 |
Why?
| Disease-Free Survival | 2 | 2021 | 656 | 0.200 |
Why?
| Immune Evasion | 1 | 2022 | 56 | 0.200 |
Why?
| Receptors, CXCR3 | 1 | 2022 | 16 | 0.190 |
Why?
| Chemokine CXCL9 | 1 | 2022 | 25 | 0.190 |
Why?
| Integrin alpha6 | 1 | 2021 | 9 | 0.190 |
Why?
| Chemokine CXCL10 | 1 | 2022 | 34 | 0.190 |
Why?
| Caspase 7 | 1 | 2021 | 20 | 0.190 |
Why?
| Immunohistochemistry | 2 | 2019 | 1669 | 0.190 |
Why?
| Integrin beta1 | 1 | 2021 | 19 | 0.190 |
Why?
| Disease Progression | 3 | 2020 | 2603 | 0.190 |
Why?
| Gene Knockdown Techniques | 2 | 2020 | 311 | 0.190 |
Why?
| Triple Negative Breast Neoplasms | 1 | 2024 | 188 | 0.180 |
Why?
| Melanoma, Experimental | 1 | 2022 | 110 | 0.180 |
Why?
| Fibronectins | 2 | 2020 | 119 | 0.180 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 34 | 0.180 |
Why?
| Mammals | 1 | 2022 | 269 | 0.180 |
Why?
| Caspase 3 | 1 | 2021 | 229 | 0.180 |
Why?
| Cytoskeletal Proteins | 1 | 2021 | 142 | 0.180 |
Why?
| Actin Cytoskeleton | 1 | 2021 | 101 | 0.170 |
Why?
| Hyaluronan Receptors | 1 | 2020 | 96 | 0.170 |
Why?
| Adipocytes | 1 | 2021 | 204 | 0.170 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2022 | 206 | 0.170 |
Why?
| Models, Biological | 3 | 2019 | 1693 | 0.170 |
Why?
| Enzyme Activation | 1 | 2021 | 799 | 0.160 |
Why?
| Maternal Age | 1 | 2020 | 122 | 0.160 |
Why?
| Pyrazoles | 2 | 2014 | 400 | 0.160 |
Why?
| Kaplan-Meier Estimate | 2 | 2020 | 857 | 0.160 |
Why?
| Estrogens | 2 | 2020 | 354 | 0.160 |
Why?
| Collagen | 2 | 2013 | 429 | 0.160 |
Why?
| Signal Transduction | 5 | 2022 | 4829 | 0.160 |
Why?
| Sulfonamides | 2 | 2014 | 500 | 0.160 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2019 | 66 | 0.160 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 937 | 0.160 |
Why?
| Genes, Reporter | 1 | 2019 | 266 | 0.160 |
Why?
| Actins | 1 | 2021 | 401 | 0.160 |
Why?
| Tumor Cells, Cultured | 1 | 2020 | 927 | 0.150 |
Why?
| Extracellular Vesicles | 1 | 2020 | 128 | 0.150 |
Why?
| Phosphorylation | 2 | 2021 | 1681 | 0.150 |
Why?
| Crosses, Genetic | 1 | 2018 | 141 | 0.150 |
Why?
| Cell Proliferation | 3 | 2020 | 2335 | 0.150 |
Why?
| Integrins | 1 | 2018 | 92 | 0.150 |
Why?
| RNA, Small Interfering | 1 | 2020 | 571 | 0.140 |
Why?
| B7-H1 Antigen | 1 | 2019 | 185 | 0.140 |
Why?
| Protein Binding | 2 | 2022 | 2097 | 0.140 |
Why?
| Podosomes | 1 | 2016 | 3 | 0.140 |
Why?
| Adaptor Proteins, Vesicular Transport | 1 | 2016 | 43 | 0.130 |
Why?
| Neoplastic Stem Cells | 1 | 2020 | 384 | 0.130 |
Why?
| Genetic Pleiotropy | 1 | 2016 | 29 | 0.130 |
Why?
| Survival Rate | 1 | 2020 | 1872 | 0.130 |
Why?
| rab GTP-Binding Proteins | 1 | 2016 | 72 | 0.130 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 872 | 0.120 |
Why?
| Melanoma | 1 | 2022 | 749 | 0.120 |
Why?
| Phenotype | 2 | 2021 | 3050 | 0.110 |
Why?
| Skin Neoplasms | 1 | 2022 | 832 | 0.110 |
Why?
| Blotting, Western | 3 | 2011 | 1168 | 0.110 |
Why?
| Dinoprostone | 1 | 2014 | 187 | 0.110 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 840 | 0.100 |
Why?
| Endothelial Cells | 1 | 2018 | 701 | 0.100 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1046 | 0.100 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2013 | 82 | 0.100 |
Why?
| Drug Design | 1 | 2013 | 155 | 0.100 |
Why?
| Hematopoietic Stem Cells | 1 | 2015 | 377 | 0.100 |
Why?
| Ibuprofen | 1 | 2011 | 80 | 0.090 |
Why?
| Risk | 2 | 2013 | 852 | 0.090 |
Why?
| Time Factors | 4 | 2020 | 6503 | 0.090 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2011 | 313 | 0.090 |
Why?
| BRCA1 Protein | 1 | 2010 | 63 | 0.080 |
Why?
| Cohort Studies | 1 | 2020 | 5369 | 0.080 |
Why?
| Macrophage Activation | 1 | 2010 | 186 | 0.080 |
Why?
| Mutation | 1 | 2019 | 3692 | 0.080 |
Why?
| Stromal Cells | 1 | 2009 | 105 | 0.080 |
Why?
| Incidence | 2 | 2020 | 2619 | 0.080 |
Why?
| Analysis of Variance | 1 | 2011 | 1271 | 0.080 |
Why?
| Tamoxifen | 1 | 2009 | 200 | 0.070 |
Why?
| Extracellular Matrix Proteins | 1 | 2009 | 141 | 0.070 |
Why?
| Gonadal Steroid Hormones | 1 | 2009 | 132 | 0.070 |
Why?
| Restriction Mapping | 1 | 2007 | 74 | 0.070 |
Why?
| Insulin-Like Growth Factor I | 1 | 2010 | 307 | 0.070 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 371 | 0.070 |
Why?
| Disease Susceptibility | 1 | 2009 | 334 | 0.070 |
Why?
| Estradiol | 1 | 2010 | 497 | 0.070 |
Why?
| Cloning, Molecular | 1 | 2007 | 522 | 0.060 |
Why?
| Cell Line | 2 | 2010 | 2731 | 0.060 |
Why?
| Recombinant Fusion Proteins | 1 | 2007 | 632 | 0.060 |
Why?
| Immunotherapy | 2 | 2022 | 585 | 0.060 |
Why?
| Phosphatidylinositol 3-Kinases | 2 | 2020 | 357 | 0.060 |
Why?
| Base Sequence | 1 | 2007 | 2134 | 0.050 |
Why?
| Young Adult | 3 | 2020 | 12320 | 0.050 |
Why?
| Adult | 6 | 2020 | 35315 | 0.050 |
Why?
| Molecular Sequence Data | 1 | 2007 | 2818 | 0.050 |
Why?
| Cell Cycle Proteins | 2 | 2020 | 580 | 0.050 |
Why?
| Neoplasms | 1 | 2016 | 2465 | 0.050 |
Why?
| Antineoplastic Agents | 1 | 2013 | 2058 | 0.050 |
Why?
| Stress Fibers | 1 | 2021 | 18 | 0.050 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2022 | 168 | 0.050 |
Why?
| Focal Adhesions | 1 | 2021 | 44 | 0.050 |
Why?
| Tumor Burden | 1 | 2022 | 282 | 0.040 |
Why?
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 22 | 0.040 |
Why?
| Feedback, Physiological | 1 | 2020 | 74 | 0.040 |
Why?
| Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.040 |
Why?
| SOXB1 Transcription Factors | 1 | 2020 | 54 | 0.040 |
Why?
| Kidney | 1 | 2007 | 1305 | 0.040 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 209 | 0.040 |
Why?
| Proteomics | 2 | 2020 | 1004 | 0.040 |
Why?
| Cell Adhesion | 1 | 2020 | 444 | 0.040 |
Why?
| Cell Communication | 1 | 2020 | 293 | 0.040 |
Why?
| Survival Analysis | 1 | 2022 | 1265 | 0.040 |
Why?
| Ki-67 Antigen | 1 | 2019 | 106 | 0.040 |
Why?
| Parity | 1 | 2019 | 120 | 0.040 |
Why?
| Hyaluronic Acid | 1 | 2020 | 212 | 0.040 |
Why?
| Rats | 3 | 2013 | 5168 | 0.040 |
Why?
| Proteins | 1 | 2024 | 936 | 0.040 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 391 | 0.040 |
Why?
| Monocytes | 1 | 2020 | 541 | 0.040 |
Why?
| Global Health | 1 | 2020 | 326 | 0.030 |
Why?
| Neoplasm Proteins | 1 | 2020 | 421 | 0.030 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2016 | 55 | 0.030 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2016 | 113 | 0.030 |
Why?
| Lymph Nodes | 1 | 2019 | 467 | 0.030 |
Why?
| Breast Feeding | 1 | 2020 | 421 | 0.030 |
Why?
| Protein Domains | 1 | 2016 | 251 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2019 | 1288 | 0.030 |
Why?
| Rats, Sprague-Dawley | 2 | 2010 | 2245 | 0.030 |
Why?
| Gene Expression Profiling | 1 | 2020 | 1687 | 0.030 |
Why?
| Bone Marrow | 1 | 2015 | 267 | 0.030 |
Why?
| Case-Control Studies | 1 | 2020 | 3326 | 0.030 |
Why?
| Risk Factors | 2 | 2019 | 9727 | 0.020 |
Why?
| Cadherins | 1 | 2013 | 186 | 0.020 |
Why?
| Middle Aged | 3 | 2020 | 30893 | 0.020 |
Why?
| Liver | 1 | 2020 | 1827 | 0.020 |
Why?
| Weaning | 1 | 2010 | 48 | 0.020 |
Why?
| MicroRNAs | 1 | 2016 | 671 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2010 | 65 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2013 | 1208 | 0.020 |
Why?
| Immunoprecipitation | 1 | 2010 | 157 | 0.020 |
Why?
| Matrix Metalloproteinases | 1 | 2010 | 89 | 0.020 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2010 | 145 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2013 | 1494 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2010 | 374 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 179 | 0.020 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 136 | 0.020 |
Why?
| Species Specificity | 1 | 2010 | 567 | 0.020 |
Why?
| Protein Transport | 1 | 2010 | 422 | 0.020 |
Why?
| Biomarkers | 2 | 2010 | 3881 | 0.020 |
Why?
| Mice, Nude | 1 | 2009 | 682 | 0.020 |
Why?
| Cytokines | 1 | 2015 | 1985 | 0.020 |
Why?
| Cell Cycle | 1 | 2010 | 581 | 0.020 |
Why?
| Mass Spectrometry | 1 | 2010 | 660 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2010 | 1284 | 0.020 |
Why?
| Cell Culture Techniques | 1 | 2009 | 345 | 0.020 |
Why?
| Fibroblasts | 1 | 2009 | 939 | 0.010 |
Why?
| Cells, Cultured | 1 | 2010 | 4008 | 0.010 |
Why?
| Adolescent | 1 | 2020 | 20213 | 0.010 |
Why?
| Retrospective Studies | 1 | 2013 | 14460 | 0.010 |
Why?
| Male | 1 | 2020 | 62883 | 0.010 |
Why?
| Aged | 1 | 2010 | 21971 | 0.010 |
Why?
|
|
Lyons's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|